Search results for "Riure"

showing 10 items of 200 documents

Refined atrial fibrillation screening and cost-effectiveness in the German population

2021

ObjectiveLittle is known on optimal screening population for detecting new atrial fibrillation (AF) in the community. We describe characteristics and estimate cost-effectiveness for a single timepoint electrocardiographic screening.MethodsWe performed a 12-lead ECG in the German population-based Gutenberg Health Study between 2007 and 2012 (n=15 010), mean age 55±11 years, 51% men and collected more than 120 clinical and biomarker variables, including N-terminal pro B-type natriuretic peptide (Nt-proBNP), risk factors, disease symptoms and echocardiographic variables.ResultsOf 15 010 individuals, 466 (3.1%) had AF. New AF was found in 32 individuals, 0.2% of the total sample, 0.5% of indivi…

AdultMalemedicine.medical_specialtyCost effectivenessCost-Benefit AnalysisPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineAtrial FibrillationNatriuretic Peptide BrainEpidemiologyHumansMedicine030212 general & internal medicineRisk factoreducationStrokeAgedHeart Failureeducation.field_of_studybusiness.industryAtrial fibrillationMiddle Agedmedicine.diseasePeptide Fragments3. Good healthStrokeHeart failureBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersHeart
researchProduct

A multiple biomarker risk score for guiding clinical decisions using a decision curve approach.

2011

Aims: We assessed whether a cardiovascular risk model based on classic risk factors (e.g. cholesterol, blood pressure) could refine disease prediction if it included novel biomarkers (C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin I) using a decision curve approach which can incorporate clinical consequences. Methods and results: We evaluated whether a model including biomarkers and classic risk factors could improve prediction of 10 year risk of cardiovascular disease (CVD; chronic heart disease and ischaemic stroke) against a classic risk factor model using a decision curve approach in two prospective MORGAM cohorts. This included 7739 men and women with 457 CVD …

AdultMalemedicine.medical_specialtyEpidemiologymedicine.drug_classBlood PressureDiseaseRisk AssessmentDecision Support TechniquesSex FactorsPredictive Value of TestsRisk FactorsInternal medicineTroponin INatriuretic Peptide BrainmedicineNatriuretic peptideHumansRisk thresholdProspective StudiesFramingham Risk Scorebusiness.industryTroponin IAge FactorsMiddle AgedPrognosisPeptide FragmentsSurgeryEuropeBlood pressureC-Reactive ProteinCholesterolCardiovascular DiseasesCohortBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean journal of preventive cardiology
researchProduct

Adrenomedullin and arterial stiffness: integrative approach combining monocyte ADM expression, plasma MR-Pro-ADM, and genome-wide association study.

2014

Background— Adrenomedullin (ADM) is a circulating vasoactive peptide involved in vascular homeostasis and endothelial function. Single nucleotide polymorphisms of the ADM gene are associated with blood pressure variability, and elevated levels of plasma midregional proadrenomedullin (MR-pro-ADM) are associated with cardiovascular diseases. Methods and Results— We investigated the sources of variability of ADM gene expression and plasma MR-pro-ADM concentrations in the general population, and their relationship with markers of atherosclerosis. MR-pro-ADM levels were assessed in 4155 individuals who underwent evaluation of carotid intima-media thickness and arterial rigidity (reflection inde…

AdultMalemedicine.medical_specialtyGenotypeTranscription Geneticmedicine.drug_classPopulationGenome-wide association studySingle-nucleotide polymorphismBiologyCarotid Intima-Media ThicknessPolymorphism Single NucleotideMonocytesArticleCohort Studieschemistry.chemical_compoundAdrenomedullinVascular StiffnessInternal medicineGene expressionGeneticsmedicineNatriuretic peptideHumansProtein PrecursorseducationGenetics (clinical)AgedCreatinineeducation.field_of_studyGene Expression ProfilingGenetic VariationMiddle Agedmedicine.diseaseAtherosclerosisAdrenomedullinEndocrinologyCarotid ArterieschemistryGene Expression RegulationArterial stiffnessLinear ModelsFemaleCardiology and Cardiovascular MedicineTranscriptomeGenome-Wide Association StudyCirculation. Cardiovascular genetics
researchProduct

Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.

2016

Heart failure (HF) incidence is rising worldwide and HF with preserved ejection fraction (HFpEF) represents nearly half of all cases. Treatment options are still limited in HFpEF in comparison to HF with reduced ejection fraction (HFrEF).We analyzed biomarkers in the general population to characterize HFpEF and HFrEF and defined a biomarker index to differentiate HFpEF from HFrEF. Growth differentiation factor-15 (GDF-15), soluble source of tumorigenicity 2 (sST2), C-reactive protein (CRP) and NT-proBNP were measured in 5000 individuals of the population-based Gutenberg Health Study (GHS). The median follow-up time for all-cause mortality was 7.3years with 213 events.Identification of subje…

AdultMalemedicine.medical_specialtyGrowth Differentiation Factor 15Population030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicineNatriuretic Peptide BrainmedicineHumans030212 general & internal medicineeducationAgedHeart Failureeducation.field_of_studyEjection fractionbiologybusiness.industryIncidence (epidemiology)C-reactive proteinTreatment optionsStroke VolumeMiddle Agedmedicine.diseasePrognosisInterleukin-1 Receptor-Like 1 ProteinPeptide FragmentsC-Reactive ProteinHeart failurebiology.proteinCardiologyBiomarker (medicine)FemaleGDF15Cardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Plasma levels of atrial natriuretic peptide and hemodynamic function in cardiac disease.

1993

Plasma concentrations of atrial natriuretic peptide were measured in eight patients with cardiac disease but normal resting right atrial pressure, during cardiac catheterization. No patient had clinical evidence of overt heart failure. An increase in peptide concentrations was observed between the aorta or the peripheral vein and the pulmonary artery. A linear relation was found between peripheral vein and pulmonary artery peptide concentration. Mean pulmonary artery and capillary wedge pressure also correlated with the peptide levels. No correlation was observed between mean right atrial pressure and peptide concentration. These findings demonstrate that atrial natriuretic peptide release,…

AdultMalemedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentRadioimmunoassayRenin-Angiotensin SystemCatecholaminesAtrial natriuretic peptideInternal medicinemedicine.arterymedicineHumansPulmonary wedge pressureCardiac catheterizationAgedAged 80 and overAortabusiness.industryLow pressure receptor zonesCentral venous pressureHemodynamicsMiddle Agedmedicine.diseaseArginine VasopressinEndocrinologyHeart failurePulmonary arterycardiovascular systemCardiologyAtrial Function LeftFemaleCardiology and Cardiovascular MedicinebusinessAtrial Natriuretic FactorInternational journal of cardiology
researchProduct

Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease

2005

As a competitive inhibitor of endothelial nitric oxide synthase, asymmetric dimethylarginine (ADMA) has been related to atherosclerotic disease. Little is known about the prognostic impact of baseline ADMA determination. In a prospective cohort of 1908 patients with coronary artery disease, we assessed baseline serum concentration of ADMA in 1874 consecutive patients with coronary artery disease. One hundred fourteen individuals developed the primary end point of death from cardiovascular causes or nonfatal myocardial infarction during a mean follow-up of 2.6±1.2 years. Median concentrations of ADMA levels were higher among individuals who subsequently developed the primary end point than …

AdultMalemedicine.medical_specialtyPhysiologymedicine.drug_classCoronary DiseaseArginineCoronary artery diseasechemistry.chemical_compoundRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansProspective StudiesMyocardial infarctionProspective cohort studyAgedbiologybusiness.industryHazard ratioC-reactive proteinMiddle Agedmedicine.diseaseConfidence intervalC-Reactive ProteinchemistryCardiovascular DiseasesCreatininebiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicineAsymmetric dimethylargininebusinessBiomarkersCirculation Research
researchProduct

The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outc…

2008

Aims We sought to determine the association between two major biomarkers, the inactive N-terminal fragment of brain natriuretic peptide (NT-proBNP) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and long-term cardiovascular outcomes in a cohort of subjects who had a myocardial infarction or unstable angina 3–36 months previously. Methods and results Plasma NT-proBNP and TIMP-1 were measured in a nested case control study of 250 randomly matched subject pairs enrolled in the long-term intervention with pravastatin in ischaemic disease (LIPID) and LIPID extended follow-up studies. Cases ( n = 250) were defined as those who had a cardiovascular death, non-fatal myocardial infarction or s…

AdultMalemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionCoronary AngiographyGastroenterologyLeukocyte CountRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansAngina UnstableAgedPravastatinTissue Inhibitor of Metalloproteinase-1Framingham Risk Scorebusiness.industryAnticholesteremic AgentsCase-control studyOdds ratioMiddle AgedPrognosisBrain natriuretic peptidePeptide FragmentsC-Reactive ProteinEndocrinologyQuartileCase-Control StudiesNested case-control studyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersPravastatinmedicine.drugEuropean Heart Journal
researchProduct

Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study

2009

Objective To examine the influence of age on the predictive value of N-terminal pro-brain natriuretic (NT-proBNP) peptide assay in acute myocardial infarction. Design Prospective observational study. Setting All intensive care units in one French region. Participants 3291 consecutive patients admitted for an acute myocardial infarction, from the RICO survey (a French regional survey for acute myocardial infarction). Main outcome measure Cardiovascular death at 1 year. Results Among the 3291 participants, mean age was 68 (SD 14) years and 2356 (72%) were men. In the study population, the median NT-proBNP concentration was 1053 (interquartile range 300-3472) pg/ml. Median values for age quart…

AdultMalemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionIschaemic Heart DiseaseDrugs: Cardiovascular SystemPredictive Value of TestsInterquartile rangeInternal medicineIntensive careNatriuretic Peptide BrainFluid Electrolyte and Acid-Base DisturbancesmedicineNatriuretic peptideHumansProspective Studiescardiovascular diseasesMyocardial infarctionProspective cohort studyAgedGeneral Environmental ScienceAged 80 and overFramingham Risk Scorebusiness.industryResearchAdult Intensive CareDiabetesGeneral EngineeringGeneral MedicineMiddle AgedPrognosismedicine.diseaseBrain natriuretic peptidePeptide FragmentsSurgeryHospitalizationCardiovascular DiseasesPredictive value of testsHypertensionGeneral Earth and Planetary SciencesFemaleFrancebusinessBiomarkersBMJ
researchProduct

Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay

2013

Abstract Background Diagnosis of acute myocardial infarction (AMI) according to the universal definition is based on ischemic symptoms, imaging findings and elevated myocardial necrosis markers, preferably cardiac troponin I/T with diagnostic threshold representing the 99th percentile of a reference population. It is not clearly defined if this should be an unselected population-based or a healthy cohort with respect to cardiac diseases. Aim of the current study was to describe the distribution of troponin I using a sensitive assay and to evaluate the impact of cardiac diseases and cardiovascular risk factors in apparently healthy individuals. Methods Troponin I was determined using a conte…

AdultMalemedicine.medical_specialtymedicine.drug_classPopulationDiseaseCohort StudiesSex FactorsReference ValuesRisk FactorsInternal medicineTroponin INatriuretic peptidemedicineHumansProspective StudiesMyocardial infarctioneducationAgededucation.field_of_studybusiness.industryTroponin IAge FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesCardiovascular DiseasesPopulation SurveillanceCohortCardiologyPopulation studyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyInternational Journal of Cardiology
researchProduct

NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke

2019

Background and Purpose— Ischemic stroke causes major disability as a consequence of neuronal loss and recurrent ischemic events. Biomarkers predicting tissue damage or stroke recurrence might be useful to guide an individualized stroke therapy. NfL (neurofilament light chain) is a promising biomarker that might be used for this purpose. Methods— We used individual data of patients with an acute ischemic stroke and clinical long term follow-up. Serum NfL (sNfL) was quantified within 24 hours after admission and after 1 year and compared with other biomarkers (GDF15 [growth differentiation factor 15], S100, NT-proBNP [N-terminal pro-B-type natriuretic peptide], ANP [atrial natriuretic peptid…

Advanced and Specialized Nursing0303 health sciencesmedicine.medical_specialtybusiness.industrymedicine.drug_classOdds ratiomedicine.disease3. Good healthBrain ischemia03 medical and health sciences0302 clinical medicineInterquartile rangeModified Rankin ScaleInternal medicineDiabetes mellitusClinical endpointmedicineNatriuretic peptideCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke030217 neurology & neurosurgery030304 developmental biologyStroke
researchProduct